

# Paola Bisceglia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/327710/publications.pdf>

Version: 2024-02-01

12  
papers

260  
citations

1307594

7  
h-index

1281871

11  
g-index

12  
all docs

12  
docs citations

12  
times ranked

484  
citing authors

#	ARTICLE	IF	CITATIONS
1	Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210816.	2.5	8
2	Italian Case Report with a Double Mutation in PSEN1 (K311R and E318G). <i>Neurology International</i> , 2022, 14, 417-422.	2.8	2
3	A New Presenilin 1 (Psen1) Mutation (p.Cys263Trp) as a Cause of Both Early and Late-Onset Alzheimer's Disease in a Large Italian Family. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6215.	4.1	4
4	Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 751-765.	3.3	0
5	Understanding the Amyloid Hypothesis in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 493-510.	2.6	77
6	Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2019, 8, 4.	8.0	5
7	Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 4333-4344.	4.0	19
8	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	3.1	34
9	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1373-1385.	2.4	8
10	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. <i>Expert Review of Proteomics</i> , 2017, 14, 809-824.	3.0	36
11	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 259-277.	3.3	13
12	Emerging drugs to reduce abnormal $\beta$ -amyloid protein in Alzheimer's disease patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 377-391.	2.4	54